Trinity Biotech (TRIB) Non-Current Debt (2009 - 2025)

Trinity Biotech has disclosed Non-Current Debt across 15 years of filings, most recently posting $83.6 million for Q2 2025.

• Non-Current Debt for Q2 2025 came in at $83.6 million, up 27.1% year-over-year; the trailing twelve-month figure through Jun 2025 was $83.6 million (up 27.1% YoY), and the FY2024 annual result was $72.4 million, up 80.49% from the prior year.
• Non-Current Debt came in at $83.6 million for Q2 2025 at Trinity Biotech, up from $72.4 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $83.6 million in Q2 2025 to a low of $31000.0 in Q4 2021.
• The 5-year median for Non-Current Debt is $46.8 million (2022), against an average of $51.8 million.
• Across the five-year window, Non-Current Debt soared 142806.45% in 2022 and tumbled 35.47% in 2023, its largest moves.
• Trinity Biotech's Non-Current Debt stood at $31000.0 in 2021, then jumped by 142806.45% to $44.3 million in 2022, then declined by 9.46% to $40.1 million in 2023, then jumped by 80.49% to $72.4 million in 2024, then climbed by 15.54% to $83.6 million in 2025.
• The last three Non-Current Debt figures came in at $83.6 million (Q2 2025), $72.4 million (Q4 2024), and $66.4 million (Q3 2024), per Business Quant data.